GHRP-6
Also known as: Growth Hormone-Releasing Peptide-6, Growth Hormone-Releasing Hexapeptide-6, His-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH2, GH-Releasing Peptide 6
Synthetic peptide GH secretagogue (growth hormone-releasing peptide); GHS-R1a agonist
What it is
GHRP-6 is a peptide people use to boost growth hormone output for muscle recovery, body composition, and general wellness. It's also used in clinical research as a diagnostic test for GH deficiency. Not FDA-approved for therapeutic use; banned by WADA; studied in organ protection and metabolic research.
The scientific side
GHRP-6 (His-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH2; MW 872.44 Da) is a synthetic hexapeptide that stimulates GH secretion by binding to the GH secretagogue receptor (GHS-R), acting through mechanisms distinct from those of GHRH (PMID 36869809; PMID 8421084; PMID 7920995). Its intracellular signalling involves protein kinase C (PKC) activation, phosphatidylinositol (PI) turnover, and mobilisation of intracellular Ca2+ (PMID 7772238; PMID 8175966). In GH3 cells, GHRP-6 induces CREB phosphorylation and GH secretion via a PKCσ-dependent pathway. GHRP-6 also upregulates Pit-1 transcription via PKC, MAPK kinase, and PKA activation. Evidence from patients with hypothalamo-pituitary disconnection indicates that its primary action is exerted at the hypothalamic level, requiring an intact hypothalamo-pituitary axis for full GH-releasing activity, though a direct pituitary action also exists (PMID 7883854; PMID 7593423). GHRP-6 also stimulates ACTH and cortisol release and has demonstrated cytoprotective, anti-inflammatory, and tissue-regenerative effects in animal models independent of GH secretion (PMID 16417467; PMID 41534456; PMID 41327290; PMID 41901314). GHRP-6 was found to bind to melanocortin MC1 and MC5 receptors in vitro, though at low affinity.
Class: Synthetic peptide GH secretagogue (growth hormone-releasing peptide); GHS-R1a agonist
Administration & storage
- Administration
- Intravenous bolus (PMID: 23099431PMID: 8421084PMID: 7883854PMID: 12809173PMID: 15817913)Intravenous infusion (PMID: 17112585)Intraperitoneal (animal studies: PMID: 16417467PMID: 26311576PMID: 30390209)Subcutaneous (animal study: PMID: 21704671)Oral/per os (human studies: PMID: 7581965PMID: 8051337; animal study: PMID: 8374685)Intranasal (human metabolite study: PMID: 25869809)Oral aquafeed (fish study: PMID: 40906090)
- Storage
- No storage conditions for GHRP-6 preparations are described in the reviewed abstracts. The LC-MS bioanalytical validation study confirmed analyte and internal standard stability under conditions experienced during real-time analysis (specific conditions not detailed in abstract).
- Cautions
- In the only identified human Phase I pharmacokinetic study (9 healthy male volunteers), atypical GHRP-6 concentration spikes were observed during the elimination phase in 4 of 9 subjects at all dose levels tested; clinical significance is unknown.,During GHRP-6 IV administration in a diagnostic study, flush symptoms were the only side effects reported; no serious adverse events were described in that study.,GHRP-6 stimulates ACTH and cortisol release in addition to GH; exaggerated ACTH/cortisol responses have been documented in Cushing's disease and Addison's disease patients, indicating caution in individuals with HPA axis disorders (PMID: 12809173; PMID: 12739742; PMID: 16832586).,GHRP-6 is listed on the WADA Prohibited List; use by competitive athletes carries doping sanction risk.,Available human safety data are limited to short-duration, single-dose IV administrations in clinical research settings. Long-term safety, chronic dosing effects, and safety of self-administered or non-IV routes in non-research settings have not been reported in the reviewed literature.,Sterile technique is essential for any injectable preparation to prevent contamination and infection.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Listed on the World Anti-Doping Agency (WADA) Prohibited List
Not stated in reviewed literature — requires manual verification
What it's studied for
- GH stimulation testing / diagnosis of GH deficiency in adults and children Human observational
- In a multicentre study of 50 GHD patients and 50 controls, peak GH < 15.0 µg/L after GHRH+GHRP-6 had 94.4% sensitivity and 98.8% specificity for GHD; the test was proposed as an alternative to the insulin tolerance test (ITT). PMID 12864804 Popovic V et al., Clinical endocrinology (2003)
- GHRP-6 alone (1 µg/kg IV) or combined with GHRH correctly identified all GHD patients as defined by ITT. GH peak cut-offs of 7 µg/L (GHRP-6 alone) and 13 µg/L (GHRP-6+GHRH) were proposed. PMID 11980622 Petersenn S et al., European journal of endocrinology (2002)
- The cut-off of 15.0 µg/L for the GHRH/GHRP-6 test could not be used in severely obese men, as GH responses were significantly reduced in obesity. GH responses in elderly men showed a non-significant negative trend. PMID 15817913 Haijma SV et al., European journal of endocrinology (2005)
- In children with pituitary stalk transection, GH responses to GHRP-6 alone or GHRH plus GHRP-6 were almost completely blocked, suggesting utility as a diagnostic tool for this condition. PMID 8887178 Pombo M et al., Journal of pediatric endocrinology & metabolism (1996)
- Review: GHRH combined with GHRP-6 (at saturating doses) described as a maximal GH stimulation test with well-defined cut-off limits, reproducible, and able to distinguish normal from GHD subjects. Obesity has a confounding effect on interpretation. PMID 18404387 Gasco V et al., Pituitary (2008)
- GH release stimulation in healthy subjects and various clinical populations (obesity, aging, thyroid disorders, Cushing's disease/syndrome, prolactinoma, Prader-Willi syndrome, polycystic ovary syndrome, type 2 diabetes, hypothyroidism, Addison's disease) Human observational
- Combined GHRH + GHRP-6 (100 µg IV each) induced a massive, synergistic GH discharge in obese subjects, demonstrating preserved somatotroph secretory capacity in obesity. PMID 8473389 Cordido F et al., Journal of clinical endocrinology and metabolism (1993)
- GH responses to GHRP-6 or GHRH+GHRP-6 did not significantly decline in late adulthood (mean age 59.5 years) compared to young adults, unlike responses to GHRH alone. PMID 7734029 Micic D et al., Clinical endocrinology (1995)
- GH release after GHRP-6 (1 µg/kg IV) was significantly decreased in thyrotoxicosis compared to controls (peak 12.6 vs 26.7 µg/L). PMID 17410412 Nascif SO et al., Pituitary (2007)
- In Cushing's disease, GH responses to GHRP-6 and GHRH were markedly blunted; ACTH/cortisol responses to GHRP-6 were enhanced compared to controls. PMID 16832586 Correa-Silva SR et al., Pituitary (2006)
- GH response to GHRP-6 (1 µg/kg IV) was significantly impaired in Prader-Willi syndrome patients compared to obese controls and short normal children. PMID 11407654 Grugni G et al., Journal of endocrinological investigation (2001)
- Hyperglycaemia significantly reduced peak GH response to combined GHRH+GHRP-6 (100 µg each IV) in type 2 diabetes patients compared to euglycaemic conditions. PMID 14693411 Micic D et al., Diabetes research and clinical practice (2004)
- In primary hypothyroidism, GH response to GHRP-6 (1 µg/kg IV) was higher than to GHRH but lower than controls. GHRH+GHRP-6 produced a significant synergistic GH increase. PMID 9156038 Pimentel-Filho FR et al., Clinical endocrinology (1997)
- GHRP-6 (2 µg/kg IV) significantly stimulated ACTH and cortisol release in Cushing's disease patients, with responses comparable to those of DDAVP. PMID 12809173 Oliveira JHA et al., Journal of endocrinological investigation (2003)
- GHRP-6 (1 µg/kg IV) induced significantly enhanced ACTH release in Addison's disease patients on glucocorticoid replacement compared to controls; effect was not maintained after 72h glucocorticoid withdrawal. PMID 12739742 Martins MRA et al., Journal of endocrinological investigation (2003)
- GH release after GHRP-6 or GHRH+GHRP-6 was fully preserved in microprolactinoma patients; macroprolactinoma patients showed blunted responses that improved after bromocriptine-induced tumour shrinkage. PMID 9509075 Popovic V et al., Clinical endocrinology (1998)
- Cytoprotection / organ protection in ischaemia-reperfusion and multiple organ failure Animal studies only
- GHRP-6 (120 µg/kg IP) pre-treatment truncated hepatic/intestinal ischaemia-reperfusion damage (neutrophilic infiltration and lipid peroxidation) by 50–85% in rats. In vitro, GHRP-6 caused a 3-fold increase in intestinal epithelial cell migration. PMID 16417467 Cibrián D et al., Clinical science (2006)
- Acute lung injury and pulmonary fibrosis prevention/treatment Animal studies only
- In LPS- and zymosan/PAF-induced mouse models, GHRP-6 reduced neutrophilic alveolitis, improved alveolar-capillary permeability, reduced IL-1β serum levels, and preserved lung parenchymal integrity with reduced collagen accumulation in the chronic scenario. PMID 41534456 Wang L et al., International immunopharmacology (2026)
- Acute kidney injury therapy via metabolic regulation Animal studies only
- A self-assembling GHRP-6 hydrogel enhanced survival of renal tubular epithelial cells in an AKI mouse model by activating the mTOR-P70 pathway and reprogramming amino acid and fatty acid metabolism (spermidine, L-glutamine, acetyl-CoA). PMID 41327290 Zhao X et al., Journal of nanobiotechnology (2025)
- Cardioprotection / post-infarct ventricular remodelling Animal studies only
- In a rat permanent coronary ligation model, GHRP-6 (minimum effective dose identified as 0.4 mg/kg in healthy rats) attenuated myocardial tissue demise, reduced interstitial fibrosis, and improved left ventricle physiology. Proteomic analysis suggested mediation by fatty acid beta-oxidation, apoptosis prevention, antio PMID 41901314 Wang L et al., Pharmaceuticals (2026)
- Stroke / cerebral ischaemia neuroprotection Animal studies only
- In a Mongolian gerbil global ischaemia model, coadministration of rhEGF and GHRP-6 (600 µg/kg IP) up to 4 hours post-insult significantly improved survival, neurological outcome, and reduced infarct volume compared to vehicle. PMID 26311576 Subirós N et al., Neurological research (2016)
- Anti-doping detection (urine metabolite analysis) Human observational
- After nasal administration, GHRP-6 was mostly excreted unchanged and detected in urine up to 23 h; metabolites were detectable for up to 12 h. Detection window depends on individual metabolism, drug form, and route of administration. PMID 25869809 Semenistaya E et al., Drug testing and analysis (2015)
- GHRP-2 and GHRP-6 were detected in urine samples from athletes. (No further abstract text available.) PMID 25809000 Cox HD et al., Drug testing and analysis (2015)
- Immunomodulation in aquaculture (Sparus aurata) Animal studies only
- Dietary GHRP-6 (500 µg/kg of feed) in sea bream over 97 days modulated endocrine and immune responses following IFA treatment: maintained stable plasma cortisol/triglycerides, enhanced circulating immunoglobulin levels, and upregulated mucosal and splenic immune genes without histological alterations. PMID 40906090 Rodríguez-Viera L et al., Biology (2025)
- GHS-R antagonist analog [D-Lys3]-GHRP-6: metabolic and anti-tumour studies Mixed
- In ovariectomised high-fat diet mice, [D-Lys3]-GHRP-6 (GHS-R antagonist; subcutaneous, 7 days) markedly decreased food intake, body weight, blood glucose, insulin, and leptin, and increased β-hydroxybutyrate and UCP-1 mRNA. PMID 21704671 Maletínská L et al., Molecular and cellular endocrinology (2011)
- Daily IP injection of [D-Lys3]-GHRP-6 (20 or 200 nmoles/mouse) transiently reduced PC3 prostate cancer xenograft volume and weight in NOD/SCID mice at 2 weeks, but effects were lost by day 18. PMID 30390209 Maugham ML et al., Endocrine (2019)
- Intravenous [D-Lys3]-GHRP-6 (6 mg/kg body weight, 7 days) in growing pigs enhanced hepatic fatty acid oxidation and gluconeogenesis, reduced body weight gain, and increased serum NEFA and insulin. PMID 37301480 Zhang H et al., Peptides (2023)
- In 6 healthy human volunteers, D-Lys-GHRP-6 (2.0 µg/kg IV bolus or infusion) did not modify spontaneous or acylated ghrelin/hexarelin-stimulated GH, PRL, ACTH, or cortisol secretion, questioning its utility as a GHS-R1a antagonist in humans. PMID 17112585 Benso A et al., Neuropeptides (2007)
Protocol
100 mcg subcutaneous injection, 3x daily (upon waking, pre-workout, and before bed). Cycle: 8-12 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Intravenous bolus | 100, 200, or 400 µg/kg body weight (single IV bolus) | Single dose | human | Research PMID 23099431 |
| Intravenous | 2 µg/kg | Single dose (bolus) | human | Research PMID 12809173 |
| Intravenous | 1 µg/kg | Single dose | human | Research PMID 12739742 |
| Intravenous | 1 µg/kg (alone or combined with GHRH 1 µg/kg) | Single dose, blood sampled over 90 min | human | Research PMID 11980622 |
| Intravenous | 1 µg/kg (GHRP-6 alone) or combined with GHRH (100 µg) | Single dose | human | Research PMID 10583306 |
| Intravenous | GHRH 100 µg + GHRP-6 93 µg (IV bolus) | Single dose, GH measured for 2 hours | human | Research PMID 15817913 |
| Intravenous | GHRH 100 µg + GHRP-6 100 µg (IV bolus) | Single dose | human | Research PMID 14693411 |
| Intravenous | 1 µg/kg (alone or combined with GHRH 1 µg/kg) | Single dose | human | Research PMID 8421084 |
| Intravenous | 100 µg (GHRP-6 alone or combined with GHRH 100 µg) | Single dose | human | Research PMID 8473389 |
| Intravenous | 90 µg (GHRP-6 alone or combined with GHRH 100 µg) | Single dose | human | Research PMID 7883854 |
| Intravenous | 1 µg/kg (alone or combined with GHRH 1 µg/kg) | Single dose | human | Research PMID 7593423 |
| Intravenous | 1 µg/kg | Single dose | human | Research PMID 8435889 |
| Oral | 300 µg/kg (oral) | Single dose | human | Research PMID 7581965 |
| Oral | 300 µg/kg (oral) | Single dose | human | Research PMID 8051337 |
| Intravenous | 2.0 µg/kg IV bolus or 2.0 µg/kg/h IV infusion (D-Lys-GHRP-6) | Single session | human | Research PMID 17112585 |
| Intraperitoneal | 600 µg/kg (GHRP-6) combined with rhEGF 100 µg/kg | Single dose or repeated per protocol; therapeutic window up to 4 h post-insult assessed | animal | Research PMID 26311576 |
| Intraperitoneal | 120 µg/kg body weight | Pre-treatment (single dose before ischaemia/reperfusion) | animal | Research PMID 16417467 |
| Not specified in abstract (administered to mice) | Multiple doses tested (acute and chronic scenarios; specific doses not detailed in available abstract text) | Acute: single dose, evolved 24 h; Chronic: up to 28 days | animal | Research PMID 41534456 |
| Not specified in abstract | 0.4 mg/kg (minimum effective dose identified in healthy rats); treatment continued 7 days post-surgery in infarct model | 7 days | animal | Research PMID 41901314 |
| Continuous administration (route not specified in abstract) | 1 mg/kg per 24 h (continuous, GHRP-6) for 14 days in female dwarf rats | 14 days | animal | Research PMID 45 |
| Intraperitoneal | 20 nmoles/mouse/day or 200 nmoles/mouse/day ([D-Lys3]-GHRP-6) | 14 days (first experiment); 18 days (second experiment) | animal | Research PMID 30390209 |
| Intravenous | 6 mg/kg body weight ([D-Lys3]-GHRP-6) | 7 days | animal | Research PMID 37301480 |
| Oral (aquafeed) | 500 µg/kg of feed (dietary, over 97 days) | 97 days | animal | Research PMID 40906090 |
| subcutaneous injection | 100 mcg | 3x daily (upon waking, pre-workout, and before bed) · 8-12 weeks | Bodybuilders and physique athletes seeking GH pulse amplification for muscle gain and recovery | [Community] |
| subcutaneous injection | 100 mcg | 2x daily (upon waking and before bed) · 8-12 weeks | General biohackers and anti-aging users seeking GH optimization with manageable hunger side effects | [Community] |
| subcutaneous injection | 100 mcg | Once daily, 30 minutes before bed · 8-12 weeks | Anti-aging and longevity-focused biohackers wanting minimal disruption and improved sleep-related GH release | [Community] |
| subcutaneous injection | 200 mcg | 3x daily (upon waking, pre-workout, and before bed) · 8-12 weeks | Advanced bodybuilders seeking maximal GH pulse output; users who have built tolerance to lower doses | [Community] |
| subcutaneous injection | 100 mcg | 3x daily, stacked with Mod GRF 1-29 100 mcg per injection · 8-12 weeks | Bodybuilders and physique athletes using GHRP+GHRH combination for synergistic GH release | [Community] |
| subcutaneous injection | 100 mcg | 3x daily, stacked with CJC-1295 with DAC 2 mg · 8-12 weeks | Bodybuilders preferring less frequent GHRH dosing; users who want sustained GHRH background with pulsatile GHRP stimulation | [Community] |
| subcutaneous injection | 100 mcg | 1-2x daily, stacked with Ipamorelin 100 mcg per injection · 8-12 weeks | Users seeking GH stimulation with reduced hunger side effects by blending GHRP agents | [Community] |
| subcutaneous injection | 100 mcg | 2-3x daily during injury recovery period · 4-6 weeks | Athletes and biohackers using GH secretagogues for soft-tissue injury repair | [Community] |
| subcutaneous injection | 50 mcg | 2x daily (morning and night) · 8-12 weeks | Beginners new to peptides, or older adults sensitive to GH side effects | [Community] |
| intramuscular injection | 100 mcg | 3x daily (upon waking, pre-workout, and before bed) · 8-12 weeks | Bodybuilders who prefer intramuscular administration for peptides | [Community] |
All studies (45)
- PMID 7734029 Human observational
GH release stimulation in healthy subjects and various clinical populations (obesity, aging, thyroid - PMID 8473389 Human observational
GH release stimulation in healthy subjects and various clinical populations (obesity, aging, thyroid - PMID 8887178 Human observational
GH stimulation testing / diagnosis of GH deficiency in adults and children - PMID 9156038 Human observational
GH release stimulation in healthy subjects and various clinical populations (obesity, aging, thyroid - PMID 9509075 Human observational
GH release stimulation in healthy subjects and various clinical populations (obesity, aging, thyroid - PMID 11407654 Human observational
GH release stimulation in healthy subjects and various clinical populations (obesity, aging, thyroid - PMID 11980622 Human observational
GH stimulation testing / diagnosis of GH deficiency in adults and children - PMID 12739742 Human observational
GH release stimulation in healthy subjects and various clinical populations (obesity, aging, thyroid - PMID 12809173 Human observational
GH release stimulation in healthy subjects and various clinical populations (obesity, aging, thyroid - PMID 12864804 Human observational
GH stimulation testing / diagnosis of GH deficiency in adults and children - PMID 14693411 Human observational
GH release stimulation in healthy subjects and various clinical populations (obesity, aging, thyroid - PMID 15817913 Human observational
GH stimulation testing / diagnosis of GH deficiency in adults and children - PMID 16832586 Human observational
GH release stimulation in healthy subjects and various clinical populations (obesity, aging, thyroid - PMID 17410412 Human observational
GH release stimulation in healthy subjects and various clinical populations (obesity, aging, thyroid - PMID 18404387 Human observational
GH stimulation testing / diagnosis of GH deficiency in adults and children - PMID 25809000 Human observational
Anti-doping detection (urine metabolite analysis) - PMID 25869809 Human observational
Anti-doping detection (urine metabolite analysis) - PMID 17112585 Mixed
GHS-R antagonist analog [D-Lys3]-GHRP-6: metabolic and anti-tumour studies - PMID 21704671 Mixed
GHS-R antagonist analog [D-Lys3]-GHRP-6: metabolic and anti-tumour studies - PMID 30390209 Mixed
GHS-R antagonist analog [D-Lys3]-GHRP-6: metabolic and anti-tumour studies - PMID 37301480 Mixed
GHS-R antagonist analog [D-Lys3]-GHRP-6: metabolic and anti-tumour studies - PMID 45
1 mg/kg per 24 h (continuous, GHRP-6) for 14 days in female dwarf rats Continuous administration (route not specified in abstract) (animal) - PMID 7581965
300 µg/kg (oral) Oral (human) - PMID 7593423
1 µg/kg (alone or combined with GHRH 1 µg/kg) Intravenous (human) - PMID 7772238
- PMID 7883854
90 µg (GHRP-6 alone or combined with GHRH 100 µg) Intravenous (human) - PMID 7920995
- PMID 8051337
300 µg/kg (oral) Oral (human) - PMID 8175966
- PMID 8374685
- PMID 8421084
1 µg/kg (alone or combined with GHRH 1 µg/kg) Intravenous (human) - PMID 8435889
1 µg/kg Intravenous (human) - PMID 9574823
- PMID 10583306
1 µg/kg (GHRP-6 alone) or combined with GHRH (100 µg) Intravenous (human) - PMID 11518797
- PMID 16417467 Animal studies only
Cytoprotection / organ protection in ischaemia-reperfusion and multiple organ failure - PMID 20407870
- PMID 22154075
- PMID 23099431
100, 200, or 400 µg/kg body weight (single IV bolus) Intravenous bolus (human) - PMID 26311576 Animal studies only
Stroke / cerebral ischaemia neuroprotection - PMID 36869809
- PMID 40906090 Animal studies only
Immunomodulation in aquaculture (Sparus aurata) - PMID 41327290 Animal studies only
Acute kidney injury therapy via metabolic regulation - PMID 41534456 Animal studies only
Acute lung injury and pulmonary fibrosis prevention/treatment - PMID 41901314 Animal studies only
Cardioprotection / post-infarct ventricular remodelling